The National Center for Clinical Trials (CENCEC) in Havana, is one of the scientific institutions affected by the economic, commercial and financial blockade imposed 55 years ago the US government to Cuba.
Exclusive to the Cuban News Agency, its director, Maria Amparo Pascual, said that the greatest impact of this genocidal policy has been the inability to interact with American laboratories and pharmaceutical industries, which could make its clinical trials on the island.
The Dr. Pascual, MA in biotechnology, said that if it were not for that coercive strategy, the Caribbean nation had more access to medicines, not only to evaluate them and then record them, but then that may be available to the public.
Another important aspect is the limitation that has CENCEC about the relationship with similar centers, especially in the United States.
There is a correlation with similar institutions but from the moment that corresponds with its headquarters in the northern nation, the blockade prevents and limits to be set or clinical trials work cooperatively multicenter, which would give ample opportunities to both countries, he said.
He also stressed that many times to apply treatments excellence, CENCEC not have the appropriate medications. Then you have to look and spend extra for the sake of the comparison treatment is optimal or excellence in disease studies, said Dr. Pascual
The CENCEC evaluating the safety and efficacy of medicines to register and others to extend such treatment to all healthcare settings, through phase four clinical trials, allowing its introduction not only controlled but also training personnel with a view to is applied properly.
The institution seeks to bring research results into clinical practice, and that fundamental value makes it different from such centers in the world, who work for industry only, while in Cuba it is also guaranteed to other industry countries and to public health, said the head researcher and assistant professor.
Currently, the Ministry of Public Health, working with the Center of Molecular Immunology, developing products, including therapeutic vaccines, monoclonal antibodies and other extension already registered as recombinant erythropoietin, he said.
With over two decades of experience, the company’s research and technological innovation in the clinical evaluation of medical and pharmaceutical, biotechnology and medical equipment products ensures scientific, ethical and methodological rigor according to the highest international standards.
Cuban News Agency, October 31, 2014
Translated by: Daysi Olano Fernandez